Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Eye, Ear, Nose and Throat›Ototoxicity

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Ototoxicity

Eye, Ear, Nose and Throat · NLM MeSH · updated 2026-11-04 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

Damage to the EAR or its function secondary to exposure to toxic substances such as drugs used in chemotherapy; immunotherapy; or radiation.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (825 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

Damage to the EAR or its function secondary to exposure to toxic substances such as drugs used in chemotherapy; immunotherapy; or radiation.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Ototoxicities; Otological Toxicity; Toxicity, Otological; Drug-Induced Ototoxicity; Drug-Induced Ototoxicities; Drug Induced Ototoxicity; Ototoxicities, Drug-Induced; Ototoxicity, Drug-Induced.

Where it fits in the MeSH classification

Broader topics
Ear Diseases; Pathologic Processes; Drug-Related Side Effects and Adverse Reactions; Radiation Injuries

Related concepts

  • Drug Therapy
  • Immunotherapy
  • Radiation

Research landscape

PubMed indexes 684 records tagged with the MeSH heading “Ototoxicity” (counts retrieved 2026-11-04). 627 of them (91.7%) were published from 2020 onward, and the busiest period so far is 2020 onward with 627 records.

Reviews account for 116 records (17.0%) and meta-analyses for 15. Randomized controlled trials number 8 (1.2%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 0 records; 2000-2009: 0 records; 2010-2019: 75 records; 2020 onward: 627 records0through 199902000-2009752010-20196272020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19990
2000-20090
2010-201975
2020 onward627
Share of records by publication typeReviews: 17.0 percent; Meta-analyses: 2.2 percent; Randomized controlled trials: 1.2 percentReviews17.0% (116)Meta-analyses2.2% (15)Randomized controlled trials1.2% (8)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 684 PubMed records
TypeRecordsShare
Reviews11617.0%
Meta-analyses152.2%
Randomized controlled trials81.2%

Method: PubMed query "Ototoxicity"[MeSH Terms] with publication-type and date filters, retrieved 2026-11-04.

Reading the evidence in eye, ear, nose and throat

Eye, hearing, nose and throat studies rely on specialist tests (visual acuity, eye pressure, audiograms, scopes) and on patient-reported symptoms, which vary between people and with age. Some conditions improve without treatment, so comparison groups matter. Nothing on this page is advice about diagnosis or treatment; sudden loss of sight or hearing needs urgent care from a qualified clinician. Check how the outcome was tested, the age of the people studied and how long they were followed.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Inhibition of ferroptosis protects House Ear Institute-Organ of Corti 1 cells and cochlear hair cells from cisplatin-induced ototoxicity
Mei H, Zhao L, Li W, Zheng Z, Tang D, Lu X, et al.
2020Research article
Design not recorded in structured metadata
117cc by
PMID 32929878 · DOI · PMC7579698
The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity
Paciello F, Fetoni AR, Mezzogori D, Rolesi R, Di Pino A, Paludetti G, et al.
2020Research article
Design not recorded in structured metadata
80cc by
PMID 31974389 · DOI · PMC6978317
ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity
Kitcher SR, Kirkwood NK, Camci ED, Wu P, Gibson RM, Redila VA, et al.
2019Research article
Design not recorded in structured metadata
75cc by
PMID 31391343 · DOI · PMC6693895
Cryopreserved Human Otic Neuronal Spheroids Self-assemble for Functional Connectivity Analysis and Long-term Ototoxicity Evaluation
Sun G, Wang Y, Wang M, Wang X, Tang M, Li D, et al.
2026Research article
Design not recorded in structured metadata
3cc by
PMID 41268681 · DOI · PMC12866767

Inhibition of ferroptosis protects House Ear Institute-Organ of Corti 1 cells and cochlear hair cells from cisplatin-induced ototoxicity [1]

Research article Mei H, Zhao L, Li W, Zheng Z, Tang D, Lu X, et al. · · 2020 · cited 117 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Ferroptosis is a recently recognized form of non-apoptotic cell death caused by an iron-dependent accumulation of lipid hydroperoxides, which plays important roles in a wide spectrum of pathological conditions.
Closing excerpt
Collectively, our study indicated that ferroptosis inhibition could alleviate the cisplatin-induced ototoxicity via inactivation of lipid peroxide radical and improvement of mitochondrial function in hair cells.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (233 words)

Ferroptosis is a recently recognized form of non-apoptotic cell death caused by an iron-dependent accumulation of lipid hydroperoxides, which plays important roles in a wide spectrum of pathological conditions. The present study was aimed to investigate the impact of ferroptosis on cisplatin-induced sensory hair cell damage. Cell viability was determined by Cell Counting Kit-8 and lactase dehydrogenase assays. The reactive oxygen species (ROS) levels were evaluated by 2,7-Dichlorodi-hydrofluorescein diacetate (DCFH-DA) and MitoSox-Red staining. Mitochondrial membrane potential (MMP) was measured by tetramethylrhodamine methyl ester (TMRM) staining. Lipid peroxidation, intracellular and mitochondrial iron were detected by Liperfluo, C11-BODIPY581/591 , FerroOrange and Mito-FerroGreen, respectively. We found that cisplatin treatment not only markedly augmented ROS accumulation, decreased the MMP, but increased lipid peroxidation and iron accumulation in House Ear Institute-Organ of Corti 1 (HEI-OC1) cells. Of note, treatment with the specific ferroptosis inhibitor ferrostatin-1 could effectively abrogate the cisplatin-induced toxicity and subsequent cell death. Specifically, the improvement of mitochondrial functions is important mechanisms for protective action of ferroptosis inhibitor against cisplatin-induced damages in HEI-OC1 cells. Moreover, inhibition of ferroptosis significantly protected murine cochlear hair cells against cisplatin damage. In addition, treatment murine cochlear hair cells with ferroptosis inducer, RSL3, significantly exacerbated cisplatin-induced damage, which could be alleviated by ROS inhibitor N-acetyl-L-cysteine. Collectively, our study indicated that ferroptosis inhibition could alleviate the cisplatin-induced ototoxicity via inactivation of lipid peroxide radical and improvement of mitochondrial function in hair cells.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 32929878 · DOI · PMC7579698

The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity [2]

Research article Paciello F, Fetoni AR, Mezzogori D, Rolesi R, Di Pino A, Paludetti G, et al. · · 2020 · cited 80 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Platinum-based agents, such as cisplatin, form the mainstay of currently used chemotherapeutic regimens for several malignancies; however, the main limitations are chemoresistance and ototoxic side effects.
Closing excerpt
Thanks to their biphasic activity of antioxidant in normal cells undergoing stressful conditions and pro-oxidant in cancer cells, these polyphenols probably engage an interplay among the key factors Nrf-2, NF-κB, STAT-3 and p53.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (199 words)

Platinum-based agents, such as cisplatin, form the mainstay of currently used chemotherapeutic regimens for several malignancies; however, the main limitations are chemoresistance and ototoxic side effects. In this study we used two different polyphenols, curcumin and ferulic acid as adjuvant chemotherapeutics evaluating (1) in vivo their antioxidant effects in protecting against cisplatin ototoxicity and (2) in vitro the transcription factors involved in tumor progression and cisplatin resistance. We reported that both polyphenols show antioxidant and oto-protective activity in the cochlea by up-regulating Nrf-2/HO-1 pathway and downregulating p53 phosphorylation. However, only curcumin is able to influence inflammatory pathways counteracting NF-κB activation. In human cancer cells, curcumin converts the anti-oxidant effect into a pro-oxidant and anti-inflammatory one. Curcumin exerts permissive and chemosensitive properties by targeting the cisplatin chemoresistant factors Nrf-2, NF-κB and STAT-3 phosphorylation. Ferulic acid shows a biphasic response: it is pro-oxidant at lower concentrations and anti-oxidant at higher concentrations promoting chemoresistance. Thus, polyphenols, mainly curcumin, targeting ROS-modulated pathways may be a promising tool for cancer therapy. Thanks to their biphasic activity of antioxidant in normal cells undergoing stressful conditions and pro-oxidant in cancer cells, these polyphenols probably engage an interplay among the key factors Nrf-2, NF-κB, STAT-3 and p53.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31974389 · DOI · PMC6978317

ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity [3]

Research article Kitcher SR, Kirkwood NK, Camci ED, Wu P, Gibson RM, Redila VA, et al. · · 2019 · cited 75 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Aminoglycoside (AG) antibiotics are widely used to prevent life-threatening infections, and cisplatin is used in the treatment of various cancers, but both are ototoxic and result in loss of sensory hair cells from the inner ear.
Closing excerpt
ORC-13661 is therefore a promising and versatile protectant that reversibly blocks the hair cell MET channel and operates across multiple species and toxins.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (196 words)

Aminoglycoside (AG) antibiotics are widely used to prevent life-threatening infections, and cisplatin is used in the treatment of various cancers, but both are ototoxic and result in loss of sensory hair cells from the inner ear. ORC-13661 is a new drug that was derived from PROTO-1, a compound first identified as protective in a large-scale screen utilizing hair cells in the lateral line organs of zebrafish larvae. Here, we demonstrate, in zebrafish larvae and in mouse cochlear cultures, that ORC-13661 provides robust protection of hair cells against both ototoxins, the AGs and cisplatin. ORC-13661 also prevents both hearing loss in a dose-dependent manner in rats treated with amikacin and the loading of neomycin-Texas Red into lateral line hair cells. In addition, patch-clamp recordings in mouse cochlear cultures reveal that ORC-13661 is a high-affinity permeant blocker of the mechanoelectrical transducer (MET) channel in outer hair cells, suggesting that it may reduce the toxicity of AGs by directly competing for entry at the level of the MET channel and of cisplatin by a MET-dependent mechanism. ORC-13661 is therefore a promising and versatile protectant that reversibly blocks the hair cell MET channel and operates across multiple species and toxins.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31391343 · DOI · PMC6693895

Cryopreserved Human Otic Neuronal Spheroids Self-assemble for Functional Connectivity Analysis and Long-term Ototoxicity Evaluation [4]

Research article Sun G, Wang Y, Wang M, Wang X, Tang M, Li D, et al. · · 2026 · cited 3 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Spiral ganglion neurons (SGNs) in the inner ear are indispensable for auditory function, and their irreversible damage causes permanent sensorineural hearing loss.
Closing excerpt
Collectively, this hONS model provides a reliable platform for investigating SGN regeneration and conducting preclinical evaluation of ototoxic drug.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (197 words)

Spiral ganglion neurons (SGNs) in the inner ear are indispensable for auditory function, and their irreversible damage causes permanent sensorineural hearing loss. Although current human pluripotent stem cell (hPSC)-derived otic lineages offer a valuable resource for SGN regeneration, they face challenges in terms of reproducibility and functional maturation. Here, a robust protocol is established to generate human otic neuronal spheroids (hONS) from cryopreserved hPSC-derived pre-placodal ectoderm (PPE) cells. Post-thaw PPE cells retained high purity and differentiation efficiency comparable to fresh PPE cells. These self-assembled hONS differentiated into functionally mature SGN-like neurons, showing specific maker expression, electrophysiological activity, AMPA receptor-mediated glutamate response, and extensive neurite extension. In tripartite cocultures incorporating murine cochlear explants and human cortical organoids, hONS formed bidirectional functional synaptic connections, validated through live-cell imaging, optogenetic stimulation, and synaptic immunostaining. Notably, hONS exhibited heightened sensitivity to ototoxic insults. Short-term cisplatin exposure induced dose-dependent alterations in cellular and calcium dynamics, whereas prolonged exposure impaired glutamatergic neural functionality and triggered progressive neuronal death. Co-treatment with sodium thiosulfate attenuated cisplatin-induced damage. The hONS model also demonstrated concentration-dependent toxicity to neomycin. Collectively, this hONS model provides a reliable platform for investigating SGN regeneration and conducting preclinical evaluation of ototoxic drug.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41268681 · DOI · PMC12866767

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents [5]
    Santos NAGD, Ferreira RS, Santos ACD · Food Chem Toxicol · 2020 · cited 142 times (Europe PMC)
  • Research article Role of mitochondrial dysfunction and oxidative stress in sensorineural hearing loss [6]
    Tan WJT, Song L · Hear Res · 2023 · cited 121 times (Europe PMC)
  • Research article Cisplatin-induced ototoxicity: From signaling network to therapeutic targets [7]
    Wang X, Zhou Y, Wang D, Wang Y, Zhou Z, Ma X, et al. · Biomed Pharmacother · 2023 · cited 119 times (Europe PMC)
  • Research article Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium [8]
    Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, Skinner R, et al. · Lancet Oncol · 2019 · cited 107 times (Europe PMC)
  • Research article Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions [9]
    Tan WJT, Vlajkovic SM · Int J Mol Sci · 2023 · cited 93 times (Europe PMC)
  • Research article Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis [10]
    Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM · Cancer Epidemiol · 2022 · cited 85 times (Europe PMC)

References

  1. Mei H, Zhao L, Li W, Zheng Z, Tang D, Lu X, et al.. Inhibition of ferroptosis protects House Ear Institute-Organ of Corti 1 cells and cochlear hair cells from cisplatin-induced ototoxicity. . 2020. PMID 32929878 · DOI · PMC7579698
  2. Paciello F, Fetoni AR, Mezzogori D, Rolesi R, Di Pino A, Paludetti G, et al.. The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity. . 2020. PMID 31974389 · DOI · PMC6978317
  3. Kitcher SR, Kirkwood NK, Camci ED, Wu P, Gibson RM, Redila VA, et al.. ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity. . 2019. PMID 31391343 · DOI · PMC6693895
  4. Sun G, Wang Y, Wang M, Wang X, Tang M, Li D, et al.. Cryopreserved Human Otic Neuronal Spheroids Self-assemble for Functional Connectivity Analysis and Long-term Ototoxicity Evaluation. . 2026. PMID 41268681 · DOI · PMC12866767
  5. Santos NAGD, Ferreira RS, Santos ACD. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food Chem Toxicol. 2020. PMID 31891754 · DOI
  6. Tan WJT, Song L. Role of mitochondrial dysfunction and oxidative stress in sensorineural hearing loss. Hear Res. 2023. PMID 37167889 · DOI
  7. Wang X, Zhou Y, Wang D, Wang Y, Zhou Z, Ma X, et al.. Cisplatin-induced ototoxicity: From signaling network to therapeutic targets. Biomed Pharmacother. 2023. PMID 36455457 · DOI
  8. Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, Skinner R, et al.. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol. 2019. PMID 30614474 · DOI · PMC7549756
  9. Tan WJT, Vlajkovic SM. Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions. Int J Mol Sci. 2023. PMID 38003734 · DOI
  10. Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis. Cancer Epidemiol. 2022. PMID 35724557 · DOI · PMC9339659

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-11-04; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-11-04.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • CardiotoxicityCardiovascular Medicine
  • Drug TherapyPharmacology
  • Drug CarriersPharmacology
  • Drug CombinationsDrugs and Chemicals
  • Drug InteractionsPharmacology
  • Drug ResiduesPublic Health and Nutrition

All 51 articles in Eye, Ear, Nose and Throat →

At a glance

684
PubMed records on this heading
92%
published since 2020
116
review articles
8
randomized trials
10
verified references below

Counts come from PubMed on 2026-11-04; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • CardiotoxicityCardiovascular Medicine
  • Drug TherapyPharmacology
  • Drug CarriersPharmacology
  • Drug CombinationsDrugs and Chemicals
  • Drug InteractionsPharmacology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support